1. Homepagina
  2. Aandelen
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. Nieuws
  7. Persberichten
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Rapport
Vertraagde tijd Japan Exchange  -  24/05 07:15:02 CEST
1991.00 JPY   -0.10%
12/05Astellas Pharma Inc. Benadrukt gegevens over geavanceerde en zeldzame kankers tijdens ASCO Annual Meeting 2022 en EHA 2022 Hybrid Congress
CI
09/05Twist Bioscience ondertekent overeenkomst voor onderzoekssamenwerking en exclusieve optielicentie met Astellas Pharma
MT
09/05Twist Bioscience sluit onderzoeks-, exclusieve optie- en licentieovereenkomst met Astellas voor antilichamen ter vermindering van tumormicro-omgeving-gemedieerde immunosuppressie
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť ASTELLAS PHARMA INC.
20/05ASTELLAS PHARMA : Confirms Unfavorable District Court Decision in LEXISCANģ 0.4mg/mL U.S. ..
PU
27/04ASTELLAS PHARMA : Changes of Representative Director and Directors
PU
27/04ASTELLAS PHARMA : Financial Results (FY2021)
PU
27/04ASTELLAS PHARMA : Supplementary Documents (FY2021)
PU
27/04ASTELLAS PHARMA : Presentation Material for Information Meeting (FY2021)
PU
26/04Astellas Oncology Now Accepting Applications for Annual C3 Prize to Cultivate Innovatio..
AQ
22/04ASTELLAS PHARMA : Notice Regarding Impairment Loss for Products under Development
PU
14/04ASTELLAS PHARMA : European Commission Approves PADCEV (enfortumab vedotin) for Locally Adv..
PU
05/04WE PUBLISHED A NEW SUSTAINABILITY SE : “Developing a sustainable society by leveragi..
PU
01/04ASTELLAS PHARMA : We published a Drug Research page.
PU
15/03ASTELLAS PHARMA : Initiatives for Gene Therapy(2,933KB)
PU
14/03WE PUBLISHED A STORY : “Reinvigorating the immune system to find new ways to cure ca..
PU
14/03ASTELLAS PHARMA : Reinvigorating the immune system to find new ways to cure cancer
PU
10/03ASTELLAS PHARMA : Meeting Script(8,030KB)
PU
10/03ASTELLAS PHARMA : Announces Completion of Acquisition of Own Shares, and Cancellation of T..
PU
09/03ASTELLAS PHARMA : Update on ukraine
PU
09/03ASTELLAS PHARMA : Presentation Material for R&D Meeting
PU
09/03ASTELLAS PHARMA : Initiatives for Gene Therapy(2,929KB)
PU
09/03ASTELLAS PHARMA : Updated “R&D meeting” Section
PU
07/03ASTELLAS PHARMA : Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolin..
PU
02/03WE PUBLISHED A STORY : “Astellas' VALUE powered by people—New Challenge of HR...
PU
02/03ASTELLAS PHARMA : ' VALUE powered by people — New Challenge of HR
PU
01/03ASTELLAS PHARMA : Meeting Script(4,467KB)
PU
01/03ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
01/03ASTELLAS PHARMA : and Seagen Announce CHMP Confirms Positive Opinion for PADCEV (enfortuma..
PU
01/03ASTELLAS PHARMA : Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent..
PU
28/02ASTELLAS PHARMA : Updated “Sustainability Meeting” Section
PU
28/02ASTELLAS PHARMA : Aiming to Enhance the Sustainability of Society and Astellas' Corporate ..
PU
28/02ASTELLAS PHARMA : Presentation Material for Sustainability Meeting
PU
17/02ASTELLAS PHARMA : New research organization structure(1,245kb)
PU
14/02Seagen and Astellas Announce Initial Results of PADCEVģ (enfortumab vedotin-ejfv) in Pa..
BU
08/02Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with L..
AQ
08/02ASTELLAS PHARMA : Announces Management Structure
PU
04/02ASTELLAS PHARMA : Initiates Charitable Donations to Support Four Organizations Focused on ..
PU
02/02ASTELLAS PHARMA : Announces Acquisition of Own Shares and Cancellation of Treasury Stock
PU
02/02ASTELLAS PHARMA : Financial Results (Q3/FY2021)
PU
02/02ASTELLAS PHARMA : Presentation Material for Information Meeting (Q3/FY2021)
PU
02/02ASTELLAS PHARMA : Supplementary Documents (Q3/FY2021)
PU
24/01ASTELLAS PHARMA : Meeting Script(3,989KB)
PU
21/01ASTELLAS PHARMA : We posted the presentation material for media briefing on Digital Transf..
PU
21/01ASTELLAS PHARMA : Digital Transformation of Astellas Pharma(3,351KB)
PU
10/01Basilea Pharmaceutica - Strong Cresemba (isavuconazole) sales by Astellas in the U.S. t..
AQ
06/01Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration ..
AQ
2021ASTELLAS PHARMA : and Seagen Receive Positive CHMP Opinion for PADCEV (enfortumab vedotin)..
PU
2021Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin..
BU
2021ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo..
PU
2021Guard Therapeutics appoints Michael Reusch as Chief Medical Officer
AQ
2021Astellas and MBC BioLabs Announce Future Innovator Prize Winners, Helping Biotech Start..
AQ
2021ASTELLAS PHARMA : Changes its Corporate Website Structure
PU
2021Astellas Applied for Selection of 'Prime Market' segment of the Tokyo Stock Exchange
AQ
2021ASTELLAS PHARMA : New Research Organization Structure
PU
2021ASTELLAS PHARMA : Presentation Material for R&D Meeting
PU
2021ASTELLAS PHARMA : Corporate Governance Report
PU
2021ASTELLAS PHARMA : Applied for Selection of “Prime Market”segment of the Tokyo ..
PU
2021ASTELLAS PHARMA : Applied for Selection of “Prime Market” segment of the Tokyo..
PU
2021ASTELLAS PHARMA : Corporate Covernance Report
PU
2021Astellas to Present Research on FLT3 Mutation, Positive Acute Myeloid Leukemia from Dia..
AQ
2021ASTELLAS PHARMA : to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia &nd..
PU
2021WE PUBLISHED A STORY : “Patient centricity at Astellas—all about action.&rdquo..
PU
2021ASTELLAS PHARMA : Patient centricity at Astellas—all about action
PU
2021ASTELLAS PHARMA : Annual Report 2021 is now available.
PU
2021ASTELLAS PHARMA : Pivotal Phase 3 Trial for Pediatric Praziquantel Completes with Positive..
PU
2021ASTELLAS PHARMA : ' Efforts Against the Spread of the Coronavirus Disease (COVID-19)
PU
2021ASTELLAS PHARMA : and Pantherna Enter into Technology Evaluation Agreement for Research of..
PU
2021PLAUSIBILITY AND UNDUE BURDEN : A New Look Insufficiency After FibroGen v Akebia
AQ
2021Earnings call script
PU
2021Financial Results (Q2/FY2021)
PU
2021Supplementary Documents (Q2/FY2021)
PU
2021Presentation Material for Information Meeting (Q2/FY2021)
PU
2021ASTELLAS PHARMA : We published our corporate brand movie on the VISION section.
PU
2021ASTELLAS PHARMA : Receives “2021 Award for Excellence in Corporate Disclosure”..
PU
2021Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
2021ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
2021ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
2021ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
1  2  3  4  5  6  7  8  9Volgende